When a commercial-stage biotech has an IV-only drug and a competitor owns the self-injection market for the same indication, a subcutaneous formulation program is not a minor label extension — it is a full second launch catalyst that expands the addressable market to include patients who prefer or require self-administration. BRIUMVI IV targets the infusion segment (~$10B anti-CD20); SC BRIUMVI would directly compete with Kesimpta's $3B+ self-injection franchise, roughly doubling TAM from one formulation change.
Track SC/oral formulation trial enrollment milestones as primary pipeline catalysts for any IV-only commercial biotech. Phase III enrollment progress is a leading indicator — 75% enrolled means data is 12-18 months away. Do not conflate "pipeline" with "speculative R&D"; a formulation conversion on a validated drug is a near-certainty delivery question, not an efficacy question. Weight accordingly in valuation. The TAM expansion should be modeled into the long-term revenue ceiling, not left as unpriced optionality.